/AVIR

AVIR Stock - Atea Pharmaceuticals, Inc.

Q: What is the analyst price target for AVIR?

Analyst price target information is not currently available for AVIR.

Q: What is AVIR's market cap?

Market capitalization information is not currently available for AVIR.

Healthcare|Biotechnology|NASDAQ

$3.14+0.32%

+$0.01 (+0.32%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+119.1%upside

Target: $6.88

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AVIR

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.16

52W High$4.02

52W Low$2.46

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	$351.37M	$48.63M
Gross Profit	$-83,367,000	$-70,090,000	$-62,390,000	$184.16M	$10.61M
Gross Margin	N/A	N/A	N/A	52.4%	21.8%
Operating Income	$-192,950,000	$-164,162,000	$-130,650,000	$138.38M	$-11,030,000
Net Income	$-168,385,000	$-135,956,000	$-115,909,000	$121.19M	$-10,947,000
Net Margin	N/A	N/A	N/A	34.5%	-22.5%
EPS	$-2.00	$-1.63	$-1.39	$1.46	$-0.13

Company Overview

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

Hold / Neutral

100%

Sell / Underperform

Analyst Consensus🔴 Bearish

0 Bullish1 Neutral/Bearish

Price Targets

Average Target

↑ 119.1% Upside

Now

Low

Average

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
August 13th 2024	Morgan Stanley	Upgrade	Equal Weight	$6.88← $2
August 10th 2023	JP Morgan	Downgrade	Underweight	-

Earnings History & Surprises

AVIR

Beat Rate

72%

Last 18 quarters

Avg Surprise

+34.8%

EPS vs Estimate

Beats / Misses

13/5

Last 12 quarters

Latest EPS

$-0.53

Q4 2025

EPS Surprise History

Q1 24

-6.8%

$-0.47vs$-0.44

Q2 24

-23.0%

$-0.75vs$-0.61

Q3 24

+37.7%

$-0.48vs$-0.77

Q4 24

+26.0%

$-0.37vs$-0.50

Q1 25

-14.3%

$-0.40vs$-0.35

Q2 25

+28.6%

$-0.40vs$-0.56

Q3 25

+4.3%

$-0.44vs$-0.46

Q4 25

-15.2%

$-0.53vs$-0.46

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 11, 2026	—	—	—	—
Q1 2026	Mar 5, 2026	$-0.49	—	—	—
Q4 2025	Nov 12, 2025	$-0.46	$-0.53	-15.2%	✗ MISS
Q3 2025	Aug 7, 2025	$-0.46	$-0.44	+4.3%	✓ BEAT
Q2 2025	May 12, 2025	$-0.56	$-0.40	+28.6%	✓ BEAT
Q1 2025	Mar 6, 2025	$-0.35	$-0.40	-14.3%	✗ MISS
Q4 2024	Nov 7, 2024	$-0.50	$-0.37	+26.0%	✓ BEAT
Q3 2024	Aug 7, 2024	$-0.77	$-0.48	+37.7%	✓ BEAT
Q2 2024	May 14, 2024	$-0.61	$-0.75	-23.0%	✗ MISS
Q1 2024	Feb 28, 2024	$-0.44	$-0.47	-6.8%	✗ MISS
Q4 2023	Nov 8, 2023	$-0.46	$-0.40	+13.0%	✓ BEAT
Q3 2023	Aug 8, 2023	$-0.47	$-0.34	+27.7%	✓ BEAT
Q2 2023	May 8, 2023	$-0.51	$-0.43	+15.7%	✓ BEAT
Q1 2023	Feb 28, 2023	$-0.45	$-0.41	+8.9%	✓ BEAT
Q4 2022	Nov 7, 2022	$-0.44	$-0.10	+77.3%	✓ BEAT
Q3 2022	Aug 8, 2022	$-0.52	$-0.38	+26.9%	✓ BEAT
Q2 2022	May 10, 2022	$-0.58	$-0.51	+12.1%	✓ BEAT
Q1 2022	Feb 28, 2022	$0.17	$1.34	+688.2%	✓ BEAT
Q4 2021	Nov 11, 2021	$-0.05	$-0.34	-580.0%	✗ MISS
Q3 2021	Aug 12, 2021	$0.01	$0.02	+300.0%	✓ BEAT

Frequently Asked Questions about AVIR

What is AVIR's current stock price?

Atea Pharmaceuticals, Inc. (AVIR) is currently trading at $3.14 per share. The stock has moved +0.32% today.

What is the analyst price target for AVIR?

The average analyst price target for AVIR is $6.88, based on 1 analyst.

What sector is Atea Pharmaceuticals, Inc. in?

Atea Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is AVIR's market cap?

Atea Pharmaceuticals, Inc. has a market capitalization of $0.25 billion, making it a small-cap company.

Does AVIR pay dividends?

No, Atea Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.